UNRESECTABLE COLON ADENOCARCINOMA
Clinical trials for UNRESECTABLE COLON ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE COLON ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE COLON ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to shrink Hard-to-Treat colorectal tumors
Disease control OngoingThis phase II trial tests whether adding the immunotherapy drug nivolumab to the standard two-drug regimen (encorafenib and cetuximab) works better at shrinking tumors in people with a specific type of advanced colorectal cancer (BRAF-mutant, microsatellite stable). About 86 part…
Matched conditions: UNRESECTABLE COLON ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Triple-Drug attack shows promise for tough colorectal cancer
Disease control OngoingThis study tests a combination of two targeted drugs (encorafenib and cetuximab) plus an immunotherapy (nivolumab) in people with a specific type of advanced colorectal cancer (BRAF V600E mutation) that is stable (MSS) and has spread or can't be removed by surgery. The goal is to…
Matched conditions: UNRESECTABLE COLON ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis study tests a combination of three drugs (cetuximab, LY3214996, and abemaciclib) in people with advanced colorectal cancer that has spread and no longer responds to standard therapy. The goal is to see if the combination can shrink tumors and improve survival. About 46 adult…
Matched conditions: UNRESECTABLE COLON ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo therapy targets hard-to-treat colorectal cancer
Disease control OngoingThis study tests a new drug, SX-682, alone and with the immunotherapy nivolumab, in people with a specific type of advanced colorectal cancer that has spread or cannot be removed. The cancer must have a RAS mutation and be microsatellite stable (MSS), which often makes it harder …
Matched conditions: UNRESECTABLE COLON ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC